Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medicixi

- PMLiVE

GSK tops Access to Medicines Index for fifth time running

Leads J&J and Novartis in 'needs-orientation' while Roche and Astellas lag

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

PMEA 2016 finalists announced

AbbVie, Bayer, Celgene and Novartis are up for the prestigious Company of the Year

Roche Basel Switzerland

Roche snags pair of FDA breakthrough designations

Accelerates approval process for NSCLC treatment Alecensa and immunotherapy Actemra

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

Bayer symbol

Bayer and Merck take high-risk heart failure drug into phase III

Embarks on final study of vericiguat despite it not meeting objectives in phase II trial

- PMLiVE

NICE backs Bayer’s Eylea as first-line BRVO treatment

Recommends visual impairment therapy over current laser treatment

- PMLiVE

Novartis’ Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

- PMLiVE

Chiesi’s Holoclar wins UK Prix Galien orphan drug award

Novartis and Astellas also scoop prizes at the prestigious ceremony

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links